FAS‑670 gene polymorphism and cervical carcinogenesis risk: A meta‑analysis

Huang,Qiaoying; Wang,Jie; Hu,Yanling

doi:10.3892/br.2013.159

FAS‑670 gene polymorphism and cervical carcinogenesis risk: A meta‑analysis

Authors:
- Qiaoying Huang
- Jie Wang
- Yanling Hu
View Affiliations

Affiliations: Graduate School, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China, Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: August 20, 2013 https://doi.org/10.3892/br.2013.159
Pages: 889-894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

FAS is a cell surface receptor that plays an important role in the etiology of cancer. Previous studies on the association between FAS‑670 polymorphism and cervical carcinogenesis failed to reach a consensus; therefore, this meta‑analysis was conducted to estimate the association of FAS‑670 polymorphism and the risk of cervical cancer. This meta‑analysis included 10 studies on FAS‑670 genotyping, including a total of 2,901 cases and 2,831 controls. The complete overdominant model was applied in our meta‑analysis [AB vs. AA: odds ratio (OR)=0.879, 95% confidence interval (CI): 0.775‑0.998, P=0.046; BB vs. AA: OR=0.903, 95% CI: 0.775‑1.052, P=0.190]. The random effects OR was 1.13 (95% CI: 0.95‑1.34, I2=52.7%, Pheterogeneity=0.03). An ethnic subgroup analysis was subsequently performed. The OR for Asians was 1.25 (6 comparisons, 95% CI: 1.05‑1.48, I2=23.5%, Pheterogeneity=0.03), whereas for Caucasians, no significant association was observed between FAS‑670 polymorphism and cervical carcinogenesis (4 comparisons, OR=0.96, 95% CI: 0.75‑1.24, I2=45.9%, Pheterogeneity=0.14).

View Figures

View References

1	Zörnig M, Hueber A, Baum W and Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta. 1551:F1–F37. 2001.
2	Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
3	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
4	Lorenz HM, Herrmann M, Winkler T, Gaipl U and Kalden JR: Role of apoptosis in autoimmunity. Apoptosis. 5:443–449. 2000. View Article : Google Scholar
5	Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:233–243. 1991. View Article : Google Scholar : PubMed/NCBI
6	Oehm A, Behrmann I, Falk W, et al: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 267:10709–10715. 1992.
7	Nagata S: Apoptosis by death factor. Cell. 88:355–365. 1997. View Article : Google Scholar : PubMed/NCBI
8	Butler LM, Hewett PJ, Butler WJ and Cowled PA: Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J Cancer. 77:1454–1459. 1998. View Article : Google Scholar : PubMed/NCBI
9	Lee SH, Shin MS, Park WS, et al: Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:3068–3072. 1999.PubMed/NCBI
10	Shimonishi T, Isse K, Shibata F, et al: Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology. 32:761–769. 2000. View Article : Google Scholar : PubMed/NCBI
11	Nunobiki O, Ueda M, Toji E, et al: Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Patholog Res Int. 2011:3640692011.PubMed/NCBI
12	Huang QR, Morris D and Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 34:577–582. 1997. View Article : Google Scholar : PubMed/NCBI
13	Sun T, Zhou Y, Li H, et al: FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 202:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
14	Kordi Tamandani DM, Sobti RC and Shekari M: Association of Fas-670 gene polymorphism with risk of cervical cancer in North Indian population. Clin Exp Obstet Gynecol. 35:183–186. 2008.
15	Scarinci IC, Garcia FA, Kobetz E, et al: Cervical cancer prevention: new tools and old barriers. Cancer. 116:2531–2542. 2010.PubMed/NCBI
16	Anorlu RI: Cervical cancer: the sub-Saharan African perspective. Reprod Health Matters. 16:41–49. 2008. View Article : Google Scholar : PubMed/NCBI
17	Moore MA, Manan AA, Chow KY, et al: Cancer epidemiology and control in peninsular and island South-East Asia - past, present and future. Asian Pac J Cancer Prev. 2:81–98. 2010.PubMed/NCBI
18	Langmár Z, Németh M and Kornya L: Cervical cancer screening in Hungary - epidemiologic, historical and methodologic aspects. Orv Hetil. 152:2063–2066. 2010.(In Hungarian).
19	Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R and Wabinga H: Part I: Cancer in indigenous Africans - burden, distribution, and trends. Lancet Oncol. 9:683–692. 2008. View Article : Google Scholar : PubMed/NCBI
20	Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S and Clifford GM: Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 131:2349–2359. 2012. View Article : Google Scholar : PubMed/NCBI
21	Pate Capps N, Stewart A and Burns C: The interplay between secondhand cigarette smoke, genetics, and cervical cancer: a review of the literature. Biol Res Nurs. 10:392–399. 2009.PubMed/NCBI
22	Dikshit R, Gupta PC, Ramasundarahettige C, et al: Cancer mortality in India: a nationally representative survey. Lancet. 12:1807–1816. 2012. View Article : Google Scholar
23	Zucchi F, da Silva ID, Ribalta JC, et al: Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 30:142–144. 2009.PubMed/NCBI
24	Kang S, Dong SM, Seo SS, Kim JW and Park SY: FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet J. 180:1–5. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ueda M, Terai Y, Kanda K, et al: Fas gene promoter -670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 16(Suppl 1): 179–182. 2006. View Article : Google Scholar : PubMed/NCBI
26	Zoodsma M, Nolte IM, Schipper M, et al: Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 3:282–290. 2005. View Article : Google Scholar : PubMed/NCBI
27	Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC and Chu TY: Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol. 99:113–118. 2005. View Article : Google Scholar : PubMed/NCBI
28	Ueda M, Hung YC, Terai Y, et al: Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol. 98:129–133. 2005. View Article : Google Scholar : PubMed/NCBI
29	Dybikowska A, Sliwinski W, Emerich J and Podhajska AJ: Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med. 14:475–478. 2004.PubMed/NCBI
30	Lai HC, Sytwu HK, Sun CA, et al: Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 103:221–225. 2003. View Article : Google Scholar : PubMed/NCBI
31	Chatterjee K, Engelmark M, Gyllensten U, et al: Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among black and mixed-ancestry South Africans. BMC Res Notes. 26:2382009. View Article : Google Scholar : PubMed/NCBI
32	Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S and Zhang Z: FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis. 30:487–493. 2009. View Article : Google Scholar : PubMed/NCBI
33	Weir BS: Genetic data analysis II: Methods for discrete population genetic data. Sunderland Mass: Sinauer Associates; 1996
34	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
35	Zintzaras E, Chatzoulis DZ, Karabatsas CH and Stefanidis I: The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet. 50:267–275. 2005. View Article : Google Scholar : PubMed/NCBI
36	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar : PubMed/NCBI
37	Engelmark MT, Renkema KY and Gyllensten UB: No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer. 112:1084–1085. 2004. View Article : Google Scholar : PubMed/NCBI
38	Lerma E, Romero M, Gallardo A, et al: Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch. 452:65–74. 2008. View Article : Google Scholar : PubMed/NCBI
39	Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH and Qiao J: Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Chin J Oncol. 31:38–41. 2009.(In Chinese).